ATH
ALTERITY THERAPEUTICS LIMITED
$0.4000
▼ -3.61%
Market cap
$92M
Turnover
$285,712
Last price
$0.4000
Day change
-3.61%
Announcements
12
Range, past year
Open 0.010 · Low 0.007 · Now 0.400 · High 0.785
Open ATH in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
ATH momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-28.
Momentum quality
38/100
Wyckoff phase
Accumulation53d
Trend stage
Distribution
1 Day
-3.6%
1 Week
-7.0%
1 Month
-23.1%
RSI
32
Avg daily range
6.3%
ALTERITY THERAPEUTICS LIMITED scores 38 out of 100 for momentum quality, a reading rated low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Distribution.
On the Wyckoff cycle it sits in Accumulation, where it has been for 53 trading days. The weekly timeframe reads Uptrend, which does not yet agree with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
What stands out
- Trend R² 0.87 — highly linear uptrend
Points to watch
- 60d drawdown -38.5%
- High volatility (ATR 6.3%)
- Risk rating: Very High
- Composite downside risk elevated
ATH announcements
Recent price-sensitive releases.
- 2026-08-31 $4.2M Options Underwriting Agreement Executed Issued Capital - Other
- 2026-08-28 Appendix 4E and 2026 Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-08-12 Granted New U.S. Composition of Matter Patent for ATH434 Progress Report
- 2026-07-30 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-09 ATH Receives A$3.98m R&D Tax Incentive
- 2026-07-07 FDA Meeting Minutes Confirm Registrational Path for ATH434
- 2026-06-09 Alterity and FDA Agree on Phase 3 Program for ATH434 in MSA
More Health Care stocks
Most traded in the same sector.